Lipid 8 iLNPs were used to
deliver CRISPR-Cas9 mRNA and sgRNA which targeted to the
PLK1 gene. The safety and excellent intracerebral diffusion
performance of lipid 8 iLNPs ensured that the survival of
murine glioblastoma multiforme (GBM) mice was extended.
The median survival was extended by approximately 50% and
the overall survival was increased by 30%. The treatment of
metastatic adenocarcinoma was executed by the EGFRtargeted
lipid 8 iLNPs. These iLNPs possessed the ability of
tumor targeting, which could increase the accumulation of
CRISPR-Cas9 mRNA and sgRNA within the tumor cells.
After a single intraperitoneal administration, 80% PLK1 gene
was edited and the overall survival of mice with high-grade
ovarian cancer malignant ascites was enhanced by 80%
. These results demonstrate the clinical potential
of CRISPR-Cas9 gene editing system can be delivered by
iLNPs for treating tumors, and provide new ideas for tumor
gene therapy.
Cat.No
DC86601
Name
Lipid 8
Chemical Properties
CAS
2226547-25-5
Formula
C44H82N2O2
MW
671.13
Storage
References
Dual-Targeted Lipid Nanotherapeutic Boost for Chemo-Immunotherapy of Cancer-Adv. Mater. 2022, 34, 2106350
Return Policy
If you are in any way unsatisfied with your purchase, you may return any item(s) within 365 days of its original purchase date.
Please provide your Order Number in the email. We strive to reply to all email inquiries within one business day.
